image credit- shutterstock
China's Qyuns Therapeutics has entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd, pursuant to which the Company grants Roche the global exclusive right to develop, manufacture, and commercialize QX031N.
The company will receive a one-time, non-refundable, and non-creditable upfront payment of $75 million and is eligible to receive up to $995 million milestone payments associated with the development, regulatory approval, and commercialisation of the product, as well as tiered royalties on potential future product sales.
QX031N is an investigational long-acting bispecific antibody that targets both human thymic stromal lymphopoietin (TSLP) and human interleukin-33 (IL-33).
TSLP and IL-33 are proteins called alarmins that are released in the body in response to external factors such as allergens, viruses, pollution, and mechanical stimuli. They have been shown to be involved in respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma, and play important roles in the inflammatory processes. QX031N is expected to be developed for the treatment of respiratory diseases such as COPD and asthma, and holds the potential to become a “First-in-class” and “Best-in-disease” therapy.
